Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance
Bioconjugate Insights · 31.03.2026 · 1 (2) · 81–85
DOI: 10.18609/bci.2026.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Insights, online erschienen am 31.03.2026. Verfasst von Ya-Chi Chen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“Instead of fighting tumor adaptation, we are using it to guide our design.”Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Ya-Chi Chen, Chief Scientific Officer, OBI Pharma, about the design of a bispecific, dual-payload ADC, and how this strategy aims to address tumor resistance, heterogeneity, and payload limitations in difficult-to-treat cancers.
Zitieren
APA
Chen, Y. (2026). Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance. Bioconjugate Insights, 1(2), 81–85. https://doi.org/10.18609/bci.2026.012
Vancouver
Chen Y. Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance. Bioconjugate Insights. 2026;1(2):81–85. doi:10.18609/bci.2026.012
BibTeX
@article{Chen2026,
author = {Chen, Ya-Chi},
title = {Dual-target, dual-payload ADCs to overcome tumor heterogeneity and resistance},
journal = {Bioconjugate Insights},
year = {2026},
volume = {1},
number = {2},
pages = {81–85},
doi = {10.18609/bci.2026.012}
}
EUVIMED